tbuckley/cabot-search huggingface dataset:
Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial.
Authors: Murtuza Bharmal, Jeremy Lambert, Jeffery Scott Russell, Celeste Lebbé, Bartosz Chmielowski, Meliessa Hennessy, Alexia Marrel, Sandra P. D'Angelo
Journal: Journal of Clinical Oncology (2019)

90 Background: MCC is a rare, aggressive skin cancer with a poor prognosis. Avelumab is the only anti–PD-L1 monoclonal antibody approved for treatment of mMCC. This qualitative research embedded in a clinical trial aimed to explore pt experiences on treatment with avelumab. Methods: All treatment-naive pts with mMCC entering the registrational, open-label, multicenter trial to investigate the clinical activity and safety of avelumab were invited to participate in optional, semistructured, 30-min phone interviews at baseline (prior to study drug administration) and at weeks 13 and 25. Interviews were conducted by trained professionals, audio-recorded, transcribed, and analyzed using a qualitative software package, ATLAS.ti V7. Key concepts identified from the baseline interview for each pt were assessed during follow-up interviews. Results: A total of 29 pts (mean age, 71 y; 76% male) completed the baseline interview; 19 pts (6 in USA, 4 in France, 5 in Italy, 3 in Germany, 1 in Australia) had ≥1 follow-up interview. The baseline interviews revealed the negative psychological burden on pts living with a symptomless disease and the hope for avelumab to be a successful therapy. Over the course of the trial, most pts reported an increased or continued sense of hope and willingness to fight MCC. Pts who self-reported their disease to be improved (n=12) also reported being stable or experiencing improvements in their ability to do their daily activities and in their physical well-being and having more energy than before starting avelumab. They also reported worrying less and being optimistic. Six pts among the 7 who reported their condition as stable (n=4) or worsened (n=3) reported a worsening of their physical well-being. Nine pts reported fatigue/tiredness on the day of and the day after receiving the avelumab infusion. The reported baseline and longitudinal experiences were similar across pts from all countries. Conclusions: This qualitative study alongside a registrational trial showed that pts experienced perceptible benefits in their physical and psychological well-being following treatment success with avelumab in mMCC. Clinical trial information: NCT02155647 part B.
Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma
Authors: Xiaodong Jia, Shanshan Lu, Zhen Zeng, Qingyan Liu, Zheng Dong, Yan Chen, Zhenyu Zhu, Zhixian Hong, Ting Zhang, Guifang Du, Jiao Xiang, Dawei Wu, Wenlin Bai, Bin Yang, Yinyin Li, Jiagan Huang, Haiyang Li, Rifaat Safadi, Yinying Lu
Journal: Hepatology (2019)

Intrahepatic cholangiocarcinoma (ICC), a type of bile duct cancer, has a high mortality rate. Gut microbiota, bile acid (BA) metabolism, and cytokines have not been characterized in patients with ICC, and better noninvasive diagnostic approaches for ICC are essential to be established. Therefore, in this study we aimed to improve our understanding of changes in gut microbiota, BA metabolism, and cytokines in patients with ICC. We found that the α-diversities and β-diversities of ICC were highest and that the abundances of four genera (Lactobacillus, Actinomyces, Peptostreptococcaceae, and Alloscardovia) were increased in patients with ICC compared with those in patients with hepatocellular carcinoma or liver cirrhosis and in healthy individuals. The glycoursodeoxycholic acid and tauroursodeoxycholic acid (TUDCA) plasma-stool ratios were obviously increased in patients with ICC. Furthermore, the genera Lactobacillus and Alloscardovia that were positively correlated with TUDCA plasma-stool ratios were combined to discriminate ICC from the other three diseases. Vascular invasion (VI) frequently led to a poor prognosis in patients with ICC. Compared with patients with ICC without VI, patients with VI had a greater abundance of the family Ruminococcaceae, increased levels of plasma interleukin (IL)-4 and six conjugated BAs, and decreased levels of plasma IL-6 and chenodeoxycholic acid. A positive correlation between plasma taurocholic acid and IL-4 was observed in patients with ICC. Plasma TUDCA was negatively correlated with the abundance of the genus Pseudoramibacter and the survival time of patients with ICC, but had no effect on tumor size, as determined in two murine tumor models. Conclusion: In this study, we identified some biomarkers, including gut microbiota, BAs and inflammatory cytokines, for the diagnosis of ICC and prediction of VI in patients with ICC.
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih <i>et al</i>
Authors: Mandana Nikpour, Molla Huq, Shereen Oon
Journal: Annals of the Rheumatic Diseases (2019)

We thank Sbeih et al for their interest in our work. In their correspondence, they show longer time taken to achieve the Lupus Low Disease Activity State (LLDAS) and ‘remission’ than the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) endpoint in a case series of 50 patients with SLE and active disease treated with intravenous belimumab 10 mg/kg.1 Sbeih et al state that the analyses we undertook in the study by Oon et al ,2 which was a post hoc evaluation of BLISS-52 and BLISS-76 trials for the LLDAS endpoint, ‘lack data on the time needed to achieve LLDAS…’. However, this is not correct. In supplementary figure 1A) of the publication by Oon et al …
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Authors: Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian, Lenora A. Pluchino
Journal: Journal of the National Comprehensive Cancer Network (2019)

Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients
Authors: F. Pietrantonio, R. Lobefaro, M. Antista, R. Miceli, A. Raimondi, S. Lonardi, L. Rimassa, S. Saggio, I. Capone, G. Farina, R. Longarini, S. Mosconi, A. Sartore Bianchi, G. Tomasello, F. Petrelli, S. Murgioni, F. Perrone, L. Barault, M. Milione, F. Di Nicolantonio, M. Di Bartolomeo, F. de Braud
Journal: Annals of Oncology (2019)
A randomised crossover comparative study of e-diary (electronic diary) versus paper and pencil collection of quality of life data in patients with locally advanced and metastatic non small cell lung cancer
Authors: A. E. Ring, S. Burbridge, K. Cheong, D. Meddis, L. Underhill, D. Cella, P. Harper
Journal: Journal of Clinical Oncology (2006)

18536 Background: Electronic diaries have been developed and facilitate collection of quality of life data. However there is concern that their use may alter the properties of the validated quality of life questionnaires which have traditionally been collated using a paper and pencil methodology. This study aimed to compare the results of e-diary and paper and pencil collection of FACT-L and EQ-5D quality of life data, and to ascertain patient preferences for the different modes of collection. Methods: Fifty patients with previously treated locally advanced or metastatic NSCLC were randomised in a 1:1 ratio to either complete a paper version of the questionnaires (FACT-L and EQ-5D) followed by the e-diary (Palm Tungsten W;CRF inc. Helsinki), or e-diary followed by paper questionnaire. Patient preference, ease of use and time for completion were recorded on a separate paper questionnaire. Results: The majority (88%) of the FACT-L and all (100%) of the EQ-5D individual question responses were within ± 1 point by the two methods, although for FACT-L 29% of patients had a total score greater than ± 6 points different by the two methods. There was no significant difference in FACT-L group mean total score for the two methods. The mean completion time was shorter for the paper and pencil than the e-diary (p &lt; 0.0001). However, most patients stated that they preferred the e-diary to paper and pencil (60% vs. 12%). Conclusions: This study suggests that the mode of administration of the FACT-L and EQ-5D had a relatively small effect on the group mean responses given to the questionnaires. However data at the individual patient level looks quite variable between mode of administration. The group results obtained using the e-diary should therefore be comparable to the originally validated paper method, with the advantages of improved patient acceptability and ease of reliable interfacing with trial databases. However care need to be taken in interpreting data at the individual level. No significant financial relationships to disclose.
Stability of Distribution of F18 Flurpiridaz After Transient Coronary Occlusion in Pigs
Authors: Rudolf A. Werner, Kazuhiro Koshino, Kenji Arimitsu, Constantin Lapa, Mehrbod S. Javadi, Steven P. Rowe, Naoko Nose, Hiroyuki Kimura, Kenji Fukushima, Takahiro Higuchi
Journal: JACC. Cardiovascular imaging (2019)
Nivo-lution in Mesothelioma
Authors: Aaron S. Mansfield, Marjorie G. Zauderer
Journal: Clinical Cancer Research (2019)

Abstract The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan. See related article by Okada et al., p. 5485
Key performance measures for colonoscopy in the Polish Colonoscopy Screening Program
Authors: Marek Bugajski, Maciej Rupinski, Paulina Wieszczy, Małgorzata Pisera, Jaroslaw Regula, Michal F. Kaminski
Journal: Endoscopy (2019)

Abstract Background The European Society of Gastrointestinal Endoscopy (ESGE) has published guidelines on key performance measures for colonoscopy. We analyzed whether those standards were met in the Polish Colonoscopy Screening Program (PCSP) and whether the monitoring was feasible. Methods We analyzed database records for 43 277 PCSP participants (25 PCSP centers) for the years 2014 – 2015. We used the guideline definitions to calculate values for all key performance measures and compared these with the proposed standards at individual, center, and program level. All data were acquired from the PCSP database, apart from complication data which was assessed from external registries. Results At the program level, four of five minimum standards and one of two target standards (no set minimum standard) were met. Adequate bowel preparation rate was 91.3 % for the whole program (range among individual centers 79.2 % – 99.2 %). Cecal intubation rate was 97.4 % (93.4 % – 99.4 %). Adenoma detection rate was 29.8 % (19.1 % – 39.1 %). An appropriate polypectomy technique was applied in 62.7 % of cases (0.4 % – 97.8 %). Regarding complications, 7-day hospitalization rate after screening colonoscopy was 0.3 % (n = 127), and 30-day all-cause mortality was 0.02 % (n = 9). Patient feedback was assessed in 66.2 % of colonoscopies (7.6 % – 81.8 %). Appropriate post-polypectomy surveillance was proposed in 95.4 % of cases (range 84.9 % – -99.7 %). It was easy to monitor 6 of 7 key performance measures within the PCSP database, but monitoring complications required the additional effort of data extraction from external registries. Conclusions The PCSP meets most proposed minimum standards at program level. Some centers need additional interventions to meet the complete set of quality standards. Use of ESGE performance measures for monitoring colonoscopy is generally feasible in the setting of the colonoscopy screening program.
Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study.
Authors: Larisa J. Geskin, Julia Scarisbrick, Martine Bagot, David Christopher Fisher, Craig Elmets, Madeleine Duvic, Marie Beylot-Barry, Ellen J. Kim, Junji Moriya, Mollie Leoni, Pier Luigi Zinzani
Journal: Journal of Clinical Oncology (2019)

e19031 Background: In the MAVORIC Phase 3 study, patients (pts) with previously treated mycosis fungoides (MF)/Sezary syndrome (SS) stage IB-IVB who received mogamulizumab (MOGA) had significantly prolonged progression-free survival and greater overall response rates (ORR) compared to pts on vorinostat (VORI) (Kim et al. Lancet Oncol 2018). Less advanced MF (stage IB/IIA) is a chronic skin malignancy that can involve blood and nodes and may require many lines of systemic therapy over the disease course. This post-hoc analysis specifically examined efficacy and safety of the recently approved MOGA in stage IB/IIA MF pts. Methods: In MAVORIC, stage IB-IVB MF/SS pts who were treated with ≥1 prior systemic therapy were randomized to MOGA or oral VORI. In the post-hoc analysis, time to next treatment (TTNT) was defined as time to any therapy excluding topical steroids or focal radiation treatment. ORR was based on global composite response in 4 disease compartments – skin, blood, lymph nodes, and viscera – achieved at 2 consecutive visits at least 8 weeks apart. Individual compartment responses were also assessed. Results: A total of 85 pts with stage IB/IIA MF were included (MOGA, IB n = 15, IIA n = 21; VORI, IB n = 27, IIA n = 22). Overall, 24% (10/42) of IB pts and 28% (12/43) of IIA pts had received ≥6 prior therapies. Median TTNT with MOGA in IB pts was 11.5 months (mo) (95% CI, 1.4,16.0) compared to 3.1 mo (95% CI, 2.7, 5.3) with VORI; in IIA pts, median TTNT was 10.1 mo (95% CI, 5.5, 12.6) and 4.9 mo (95% CI, 2.4, 8.0), respectively. ORR in IB pts receiving MOGA and VORI was 20% (3/15) and 18.5% (5/27), respectively; ORR in IIA was 19% (4/21) and 0% (0/22), respectively. With respect to stage IB and IIA, compartmental response rates with MOGA were: skin (20% [3/15], 38% [8/21]), blood (0% [0/2], 75% [6/8]), and lymph node (0% [0/0], 15% [3/20]), respectively. Adverse events were generally manageable and consistent with the ITT population. Conclusions: Though MAVORIC was not powered to determine treatment effect by disease stage, this post-hoc analysis of TTNT, ORR, and compartmental response in stage IB/IIA demonstrates meaningful clinical benefit with MOGA in previously treated, less advanced MF pts. Clinical trial information: NCT01728805.
Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer
Authors: Martin Ries, Fadi Khreish, Guy Berchem, Samer Ezziddin
Journal: Clinical Nuclear Medicine (2019)

Abstract Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.
Combined Cerebral Microbleeds With Lacunar Infarctions in Familial Cerebral Cavernous Malformations
Authors: Qi Wang, Lingchao Meng, Zhaoxia Wang
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 18931: Toward Closed Loop Mechanical CPR: Regression Tree Model Predicts Carotid Blood Flow in a Swine Model of Cardiac Arrest
Authors: Joshua W Lampe, Subash Padamanaban, Theodoros P Zanos
Journal: Circulation (2017)

Introduction: Current mechanical CPR devices deliver one-size-fits-all CPR, following internationally recognized CPR guidelines. There is evidence that patient tailored CPR is more effective than o...
Abstract 13514: Serial Quantitative Assessment of Thrombogenicity in LVAD Recipients: A Case for Personalized Antithrombotic Therapy
Authors: Palak Shah, Kevin Bliden, Udaya Tantry, Sheila Phillips, Christopher McLeod, Ramesh Singh, Christopher O Connor, Paul Gurbel
Journal: Circulation (2016)

Introduction: Bleeding and thrombotic complication affect between 25-40% of left ventricular assist device (LVAD) recipients. Measures of thrombogenicity such as maximum platelet-fibrin clot strength (MAKH), endogenous thrombin potential (ETP) and platelet reactivity may indicate thrombotic and bleeding risk in patients on LVAD support and may vary after LVAD implantation. Methods: We prospectively assessed thrombogenicity using the novel point-of-care (TEG-6S) with PlateletMapping and the calibrated automated thrombogram (CAT) in 31 patients before and serially after LVAD implantation (HeartWare HVAD, n = 17; Heartmate II, n = 14). All LVAD patients were on aspirin 325mg/daily and warfarin (INR 2.0 to 2.5) therapy. Standard hematologic and hemolysis laboratories were compared. Results: Markers of thrombogenicity were highly variable post-LVAD. Overall, in the acute phase, MAKH, and maximum ADP-, and arachidonic acid (AA)-induced clot strength increased (p &lt; 0.05, Table) and returned to near baseline by ≥3 months. Despite target INR values at ≥ 3 months (2.0±0.3) and antiplatelet therapy, the R-time (7.1±1.8min) remained within the normal range. Hypercoagulable patients (MAKH≥69mm) had higher endogenous thrombin potential, peak thrombin generation, WBC count, and LDH (p≤0.05). Conclusions: A state of heightened thrombogenicity indicated by high MAKH and high platelet reactivity are present in the acute phase after LVAD implantation and in selected patient during the chronic phase despite therapy with warfarin/aspirin. These findings suggest that intensification of antithrombotic therapy in a personalized fashion based on sensitive thrombogenicity testing, rather than INR should be investigated to mitigate adverse events.
Mechanisms and therapeutic strategies for non‐T2 asthma
Authors: Eric Sze, Anurag Bhalla, Parameswaran Nair
Journal: Allergy (2019)

Abstract Non‐T2 asthma is traditionally defined as asthma without features of T2 asthma. The definition is arbitrary and is generally based on the presence of neutrophils in sputum, or the absence (or normal levels) of eosinophils or other T2 markers in sputum (paucigranulocytic), airway biopsies or in blood. This definition may be imprecise as we gain more knowledge from applying transcriptomics and proteomics to blood and airway samples. The prevalence of non‐T2 asthma is also difficult to estimate as most studies are cross‐sectional and influenced by concomitant treatment with glucocorticosteroids, and by the presence of recognized or unrecognized airway infections. No specific therapies have shown any clinical benefits in patients with asthma that is associated with a non‐T2 inflammatory process. It remains to be seen if such an endotype truly exists and to identify treatments to target that endotype. Meanwhile, identifying intense airway neutrophilia as an indicator of airway infection and airway hyperresponsiveness as an indicator of smooth muscle dysfunction, and treating them appropriately, and not increasing glucocorticosteroids in patients who do not have obvious T2 inflammation, seem reasonable.